Business Overview: Nephros, Inc. (NASDAQ: NEPH)

---

Executive Summary

Nephros, Inc. is a commercial-stage water technology company that designs, manufactures, and sells point-of-use water filtration products, with a particular focus on medical-grade infection control filtration for hospitals and healthcare facilities, alongside a commercial/industrial filtration line.

Headquartered in South Orange, New Jersey, Nephros is small (36 full-time employees, roughly $18.8 million in fiscal 2025 net revenue) but notable for having turned durably profitable after a long history of losses (reflected in a $143.1 million accumulated deficit), growing revenue 33% year-over-year in fiscal 2025 on the strength of its FDA-cleared medical filtration line and an expanding direct sales and service footprint.

---

1. Core Business Model & How They Work

Nephros designs point-of-use filters and sells them primarily through a mix of independent distributors (value-added resellers, or VARs) and a growing direct sales force, while outsourcing manufacturing of its core filter media to a single external partner.

[ Filter Design & FDA Clearance ] ➡️ [ Contract Manufacturing (Medica S.p.A.) ] ➡️ [ VAR Distributors + Direct Sales Force ] ➡️ [ Hospital/Commercial End User ] ➡️ [ Recurring Filter Replacement & Service ]

Key Operational Drivers

1. Single-Source Supply Dependency: Nephros does not manufacture its own medical filter media; it relies on Medica S.p.A. as a single-source supplier, recently under an extended long-term supply agreement that management says supports multi-year growth — but this also concentrates meaningful supply and tariff risk in one relationship.
2. FDA-Regulated, Class II Medical Devices: Nephros's medical infection-control filters (0.1-micron microfilters and 0.005-micron ultrafilters) and dialysis water ultrafilters are FDA 510(k)-cleared Class II devices, giving the medical line a real regulatory moat relative to unregulated commercial filtration.
3. Recurring Replacement Revenue: Because filters require periodic replacement, Nephros benefits from a recurring, consumable-driven revenue stream layered on top of initial system placements — reinforced by the company's recent build-out of in-house installation and replacement services.
4. Expanding Beyond Healthcare: Management has emphasized growth "beyond traditional healthcare" into foodservice, hospitality, laboratories, and other commercial/industrial settings, diversifying away from its historical hospital-centric base.

---

2. Business Segments

Nephros operates as a single reporting segment but describes its business across two product lines with distinct end markets; no formal segment revenue split is disclosed.

┌───────────────────────────────┐
│          Nephros, Inc.         │
└───────────────┬────────────────┘
                │
     ┌──────────┴──────────┐
     ▼                      ▼
┌─────────────────┐   ┌─────────────────────┐
│  Medical Line     │   │  Commercial Line      │
│ (hospitals,       │   │ (foodservice,          │
│  dialysis centers) │  │  hospitality, labs,    │
│                    │   │  other commercial)     │
└─────────────────┘   └─────────────────────┘

• Medical Line — infection-control microfilters and ultrafilters plus dialysis water ultrafilters, sold mainly to hospitals, healthcare facilities, and dialysis settings; FDA 510(k)-cleared Class II devices.
• Commercial Line — filters targeting taste, odor, scale, particulates, lead, cysts, and Total PFAS, sold into foodservice, hospitality, laboratories, manufacturing, aviation, and government buildings.

---

3. Product Portfolio

---

4. Competitive Landscape

Nephros competes in two fairly different arenas depending on product line.

Competitors by Line

Medical / Microbiological Filtration

• Key Competitors: Cytiva (formerly Pall Corporation), Aquatools, Aquamedix, i3.
• Dynamics: Cytiva, backed by Danaher, is a much larger, diversified life-sciences filtration player; Nephros competes on being a focused, FDA-cleared specialist in hospital point-of-use infection control rather than a broad life-sciences filtration portfolio.

Commercial Water-Quality Filtration

• Key Competitors: 3M Company, Pentair.
• Dynamics: Both are vastly larger, diversified industrial/consumer filtration conglomerates. Nephros's commercial line is a small niche player here, competing on specific contaminant claims (e.g., Total PFAS) rather than scale or brand recognition.

---

5. Strategic Strengths & Risks

Strategic Strengths

• FDA Clearance as a Real Barrier: Class II medical device clearance for its infection-control filters is a genuine regulatory moat that a generic commercial filter maker cannot simply replicate without going through the same process.
• Reorder/Recurring Revenue Dynamics: Management specifically credited higher reorder rates and an expanded sales-associate footprint for 2025's growth, pointing to real, if modest, customer retention economics.
• Return to Sustained Profitability: Net income reached $1.2 million in fiscal 2025 (versus $74,000 in 2024) and Adjusted EBITDA nearly tripled to $1.6 million, evidence the business model has crossed into durable, if still small, profitability.

Strategic Risks

1. Single-Source Supplier Concentration: Nephros does not manufacture its medical filter media and depends entirely on Medica S.p.A.; any disruption to that relationship would directly threaten its core medical product line.
2. Tariff Exposure: Management explicitly cited tariffs on Italian imports (tied to the Medica relationship) as having eroded margins in the second half of 2025; while the rate was later cut from 15% to 10% (effective February 2026), management flagged continued unpredictability in U.S. tariff policy.
3. Customer Concentration: The top three customers accounted for 44% of 2025 revenue, up from 36% in 2024 — a rising concentration trend that increases dependence on a small number of distributor relationships.
4. Small Scale: With only 36 full-time employees and ~$18.8 million in revenue, Nephros has limited resources to compete against much larger filtration companies like 3M, Pentair, or Danaher's Cytiva if any of them chose to compete more aggressively in its niche.

---

6. Financial Overview

---

7. Summary Conclusion

Nephros has built a small but genuinely differentiated niche: FDA-cleared, medical-grade point-of-use water filtration sold mostly through distributors into hospitals and healthcare facilities, now diversifying into foodservice, hospitality, and other commercial settings. Fiscal 2025 marked a real inflection — 33% revenue growth, a return to solid net income, and nearly tripled Adjusted EBITDA — built on reorder strength, an expanded sales footprint, and an extended supply agreement with its key manufacturing partner, Medica S.p.A.

The company's biggest forward risk is concentration risk in two forms: a single-source supplier relationship that underpins its entire medical product line, and a top-three-customer base that now represents 44% of revenue. If Nephros can keep growing its direct sales and service footprint while managing tariff and supplier risk, its regulatory moat in medical filtration gives it a credible, if narrow, path to continued profitable growth; any disruption on the supply side would hit disproportionately hard given the company's small scale.